New Lung Cancer Biomarkers Identified
“One of the newest types of cancer drugs, immunotherapies called immune checkpoint inhibitors, has transformed the treatment of lung cancer over the last decade — dramatically improving the survival of some patients with the most common form of this disease, non-small cell lung cancer (NSCLC). However, only about 20 percent of patients experience a benefit from these immunotherapies.”
Post–COVID-19 Infection Remains a Concern in Patients With Cancer
“Many questions remain unanswered about COVID-19, and we are now experiencing another problem—postacute sequelae of SARS-CoV-2 infection, also referred to as post–COVID-19 condition or post-COVID syndrome.”
UM Researcher Uses Ai To Understand Lung Cancer Cell Vulnerabilities
“MISSOULA – A scientific team that includes University of Montana biologist Mark Grimes recently used artificial intelligence to better understand how protein groups in lung cancer cells regulate cell division and metabolism.”
New CAR T-Cell Strategy Highly Effective Against Small Cell Lung Cancer in Preclinical Study
“BUFFALO, N.Y. — A new approach to chimeric antigen receptor T-cell (CAR T) therapy has shown great promise against small cell lung cancer (SCLC) in a preclinical study. The findings cover new ground in our understanding of how CAR T can be employed against solid-tumor cancers, and provide support for further studies in cancer patients.”
Why Early Detection of Lung Cancer is So Important
“CHICAGO — Lung cancer is the leading cause of cancer death in the United States. While early detection can vastly improve a patient’s chances to lead a full and healthy life, the majority of those who are high-risk are not getting screened.”
Lung cancer evolution is different in people who have and haven’t smoked
“This immunofluorescence image shows the presence of a specific subset of T cells (tissue-resident memory T cells, TRM) in the lung of smoker patients. The TRM cells are represented here in aqua and red, the lung airways are depicted in pink, and the cell nuclei are depicted in dark blue. Credit: WEHI Researchers”
Dr Tamta Makharadze Discusses EMPOWER-Lung 3 Data for Frontline Cemiplimab Plus Chemo in Advanced NSCLC
“The benefits of adding cemiplimab (Libtayo, Regeneron) to platinum-doublet chemotherapy in the frontline setting for patients with advanced non advanced non–small cell lung cancer (NSCLC) was sustained after more than 2 years, regardless of histology or level of PD-L1 expression, according to follow-up data from the phase 3 EMPOWER-Lung 3 trial (NCT03409614).”
Preclinical study reveals a potential new therapeutic approach to treating common lung cancer
“Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated in a preclinical study a potential new therapeutic approach to treating the most common form of lung cancer.”
Pragmatica-Lung Study Aims to Streamline Cancer Trials
“A novel clinical trial design is being tested to streamline cancer trials and allow quicker follow up of promising results. The Pragmatica-Lung study is a Phase III trial of a combination of ramucirumab and the imunotherapy pembrolizumab for advanced non-small cell lunger cancer (NSCLC). Both drugs are already FDA approved and promising data emerged last summer from a Phase II study of this combination in advanced non-small cell lung cancer (NSCLC).”
Most deprived communities more likely to receive early lung cancer diagnosis thanks to NHS trucks
“For the first time ever, new data shows more than a third of people diagnosed with lung cancer from the most deprived fifth of England were diagnosed at stage one or two in 2022 (34.5%) – up from 30% in 2019.”
